Summary
A major drawback of infusions of the vinca alkaloids is the lengthy period of hospitalization which is often required for this novel technique of cancer therapy. A potentially useful system to deliver outpatient therapy has been investigated in a preclinical study. A self-contained infusion pump powered by a self-charging fluorocarbon system has been implanted SC in three dogs. The performance of two pumps which had been factory-calibrated to deliver 2.5 and 4.5 ml/day, respectively, was evaluated during 22 infusions of the vinca alkaloids (vincristine, 7; vinblastine, 7; and vindesine, 8). Infusions were given over a 5- to 7-day period and were repeated at 3-week intervals. No malfunctioning of the pumps occurred in over 500 cumulative days of use. The flow rates of the pumps were quite stable except in one animal whose increased flow rate was probably a consequence of fever due to self-induced inflammation about the pump pocket. No local or distant tissue reactions to the pump were observed. Decompostion of vincristine and vinblastine in the infusate at the end of 5- or 7-day infusions was minimal as determined by high-pressure liquid chromatography. The amount of decomposition of vindesine in the infusate was variable. Steady-state concentrations of vincristine during infusion were always > 10-9 M, and were similar to those previously determined in our clinical infusion trials using a dosage of 0.5 mg/m2/day. Clinical evaluation of this system for prolonged infusions of vincristine and other vinca alkaloids appears to be warranted.
Similar content being viewed by others
References
Bayssas M, Gouveia J, Ribaud P, Musset M, de Vassal F, Pico JL, de Luca L, Misset JL, Machover D, Belpomme D, Schwarzenberg L, Jasmin C, Hyat M, Mathé G (1979) Phase II trial with vindesine for regression induction in patients with leukemias and hematosarcomas. Cancer Chemother Pharmacol 2:247–255
Blackshear PJ, Rohde TD, Prosl F, Buchwald H (1979) The implantable infusion pump: A new concept in drug delivery. Med Prog Technol 6:149–161
Bodey GP, Yap HY, Yap BS, Valdivieso M (1980) Continuous infusion vindesine in solid tumors. Cancer Treat Rev 7:39–45
Dakhil S, Ensminger W, Kindt G, Niederhuber J, Chandler W, Greenberg H, Wheeler R (1981) Implanted system for intraventricular drug infusion in central nervous system tumors. Cancer Treat Rep 65:401–411
Ensminger W, Niederhuber J, Dakhil S, Thrall J, wheeler R (1981) Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep 65:393–400
Jackson DV, Bender RA (1978) The clinical pharmacology of the vinca alkaloids, epipodophyllotoxins, and maytansine. In: Pinedo HM (ed) Clinical pharmacology of anti-neoplastic drugs. North-Holland Biomedical Press, Amsterdam, pp 277–293
Jackson DV, Bender RA (1979) Cytotoxic thresholds of vincristine in a murine and human leukemia cell line in vitro. Cancer Res 39:4346–4349
Jackson DV, Sethi VS, Spurr CL, Willard V, White DR, Richards F, Stuart JJ, Muss HB, Cooper MR, Homesley HD, Jobson VW, Castle MC (1981a) Intravenous vincristine infusion: Phase I trial. Cancer 48:2559–2564
Jackson DV, Sethi VS, Spurr CL, White DR, Richards F, Stuart JJ, Muss HB, Cooper MR, Castle MC (1981b) Pharmacokinetics of vincristine infusion. Cancer Treat Rep 65:1043–1048
Paschold EH, Jackson DV, Spurr CL, Cooper MR, Richards F, White DR, Muss HB, Stuart JJ, Case LD, Pope EK (1982) Continuous infusion of vincristine (VCR) and vinblastine (VLB) in refractory lymphoma: A phase II study. Proc Am Soc Clin Oncol 1:159
Sethi VS, Burton SS, Jackson DV (1980) A sensitive radioimmunoassay for vincristine and vinblastine. Cancer Chemother Pharmacol 4:183–187
Yap HY, Blumenschein GR, Keating MJ, hortobagyi GN, Tashima CK, Loo TL (1980) Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 64:279–283
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jackson, D.V., Barringer, M.L., Rosenbaum, D.L. et al. Continuous intravenous infusion of vinca alkaloid using a subcutaneously implanted pump in a canine model. Cancer Chemother. Pharmacol. 10, 217–220 (1983). https://doi.org/10.1007/BF00255767
Issue Date:
DOI: https://doi.org/10.1007/BF00255767